Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Roberta Bottino, Andreina Carbone, Antonello D’Andrea, Biagio Liccardo, Giovanni Cimmino, Egidio Imbalzano & Vincenzo Russo. (2022) Pharmacokinetic determinants for the right dose of antiarrhythmic drugs. Expert Opinion on Drug Metabolism & Toxicology 18:3, pages 165-176.
Read now
Read now
Cameron D. Thomas & Julie A. Johnson. (2020) Pharmacogenetic factors affecting β-blocker metabolism and response. Expert Opinion on Drug Metabolism & Toxicology 16:10, pages 953-964.
Read now
Read now
Saskia N de Wildt. (2011) Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opinion on Drug Metabolism & Toxicology 7:8, pages 935-948.
Read now
Read now
Emilio Sternieri, Ciro Pio Rosario Coccia, Diego Pinetti, Simona Guerzoni & Anna Ferrari. (2006) Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opinion on Drug Metabolism & Toxicology 2:6, pages 981-1007.
Read now
Read now
T. Yamamoto, N. Hagima, M. Nakamura, Y. Kohno, K. Nagata & Y. Yamazoe. (2004) Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs. Xenobiotica 34:7, pages 687-703.
Read now
Read now
Gurvinder Singh Rekhi, Natalie D. Eddington, Michael J. Fossler, Paul Schwartz, Lawrence J. Lesko & Larry L. Augsburger. (1997) Evaluation of in Vitro Release Rate and in Vivo Absorption Characteristics of Four Metoprolol Tartrate Immediate-Release Tablet Formulations. Pharmaceutical Development and Technology 2:1, pages 11-24.
Read now
Read now
M. J. DE GROOT, G. J. BIJLOO, F. A. A. VAN ACKER, C. FONSECA GUERRA & J. G. SNIJDERS. (1997) Extension of a predictive substrate model for human cytochrome P4502D6. Xenobiotica 27:4, pages 357-368.
Read now
Read now
D. F. V. LEWIS, P. J. EDDERSHAW, P. S. GOLDFARB & M. H. TARBIT. (1997) Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102 : structural studies on specific CYP2D6substrate metabolism. Xenobiotica 27:4, pages 319-340.
Read now
Read now
M. J. Humphrey & D. A. Smith. (1992) Role of metabolism and pharmacokinetic studies in the discovery of new drugs—present and future perspectives. Xenobiotica 22:7, pages 743-755.
Read now
Read now
B. C. Foster, H. S. Buttar, S. A. Qureshi & I. J. McGilveray. (1989) Propranolol Metabolism by Cunninghamella Bainieri. Xenobiotica 19:5, pages 539-546.
Read now
Read now
G. Muralidharan, K. K. Midha, G. McKay, E. M. Hawes & T. Inaba. (1989) Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. Xenobiotica 19:2, pages 189-197.
Read now
Read now
Elizabeth M. J. Gillam & Paul E. B. Reilly. (1988) Phenacetin O-deethylation by human liver microsomes: Kinetics and propranolol inhibition. Xenobiotica 18:1, pages 95-104.
Read now
Read now
Yukio Horai, Takashi Ishizaki, Michel Eichelbaum, Keitaro Hashimoto, Kan Chiba & Hans J. Dengler. (1988) Further Analysis of Sparteine Oxidation in a Japanese Population and Comparison with Data Observed in Different Ethnic Populations. Xenobiotica 18:9, pages 1077-1084.
Read now
Read now
Articles from other publishers (40)
Simeon Rüdesheim, Jan-Georg Wojtyniak, Dominik Selzer, Nina Hanke, Felix Mahfoud, Matthias Schwab & Thorsten Lehr. (2020) Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. Pharmaceutics 12:12, pages 1200.
Crossref
Crossref
Thirumurthy Velpandian & Govindasamy Kumaramanickavel. 2016. Pharmacology of Ocular Therapeutics. Pharmacology of Ocular Therapeutics
65
82
.
Walter Krauwinkel, James Dickinson, Marloes Schaddelee, John Meijer, Reiner Tretter, Jeroen van de Wetering, Gregory Strabach & Marcel van Gelderen. (2013) The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. European Journal of Drug Metabolism and Pharmacokinetics 39:1, pages 43-52.
Crossref
Crossref
Lauren Walker, Vincent Yip & Munir Pirmohamed. 2014. Handbook of Pharmacogenomics and Stratified Medicine. Handbook of Pharmacogenomics and Stratified Medicine
405
435
.
C. F. Samer, K. Ing Lorenzini, V. Rollason, Y. Daali & J. A. Desmeules. (2013) Applications of CYP450 Testing in the Clinical Setting. Molecular Diagnosis & Therapy 17:3, pages 165-184.
Crossref
Crossref
Shu-Feng Zhou. (2009) Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. Clinical Pharmacokinetics 48:11, pages 689-723.
Crossref
Crossref
MJ Bijl, LE Visser, RHN van Schaik, JA Kors, JCM Witteman, A Hofman, AG Vulto, T van Gelder & BHCh Stricker. (2008) Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in β-Blocker Users. Clinical Pharmacology & Therapeutics 85:1, pages 45-50.
Crossref
Crossref
S. K. Jin, H. J. Chung, M. W. Chung, J.-I. Kim, J.-H. Kang, S. W. Woo, S. Bang, S. H. Lee, H. J. Lee & J. Roh. (2008)
Influence of
CYP2D6*10
on the pharmacokinetics of metoprolol in healthy Korean volunteers
. Journal of Clinical Pharmacy and Therapeutics 33:5, pages 567-573.
Crossref
Crossref
Angela Seeringer, Jürgen Brockmöller, Steffen Bauer & Julia Kirchheiner. (2008) Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. European Journal of Clinical Pharmacology 64:9, pages 883-888.
Crossref
Crossref
A. Seeringer & J. Kirchheiner. (2008) CYP2D6-, CYP2C9- und CYP2C19-basierte ArzneimitteldosisanpassungenCYP2D6-, CYP2C9- and CYP2C19-based dose adjustments. Der Internist 49:7, pages 877-883.
Crossref
Crossref
M.C. Dumasia. (2006) In vivo biotransformation of metoprolol in the horse and on-column esterification of the aminocarboxylic acid metabolite by alcohols during solid phase extraction using mixed mode columns. Journal of Pharmaceutical and Biomedical Analysis 40:1, pages 75-81.
Crossref
Crossref
Ashish Sharma, Sylvie Pilote, Pierre M. Bélanger, Marie Arsenault & Bettina A. Hamelin. (2004) A convenient five‐drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study. British Journal of Clinical Pharmacology 58:3, pages 288-297.
Crossref
Crossref
Benjamin M. Schaefer, Vincent Caracciolo, William H. Frishman & Pamela Charney. (2003) Gender, Ethnicity, and Genes in Cardiovascular Disease.. Heart Disease 5:3, pages 202-214.
Crossref
Crossref
Nattee Sirisuth & Natalie D. Eddington. (2002) The influence of first pass metabolism on the development and validation of an IVIVC for metoprolol extended release tablets. European Journal of Pharmaceutics and Biopharmaceutics 53:3, pages 301-309.
Crossref
Crossref
Line Labbe, Caroline Sirois, Sylvie Pilote, Marie Arseneault, N. Robitaille, Jacques Turgeon & Bettina Hamelin. (2000) Pharmacogenetics 10:5, pages 425-438.
Crossref
Crossref
Bettina A. Hamelin, Peter G. Dorson, Dennis Pabis, Daniel Still, Roch‐H. Bouchard, Emmanuel Pourcher, Jimmy Rail, Jacques Turgeon & M. Lynn Crismon. (2012) CYP2D6 Mutations and Therapeutic Outcome in Schizophrenic Patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 19:9, pages 1057-1063.
Crossref
Crossref
Amy M. Meadowcroft, Kristin M. Williamson, J. Herbert Patterson & John A. Pieper. (2012) Pharmacogenetics and Heart Failure: A Convergence with Carvedilol. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 17:4, pages 637-639.
Crossref
Crossref
Ken Woodhouse. (2008) Drug handling by the aging liver: past work and future directions. Reviews in Clinical Gerontology 6:3, pages 215-223.
Crossref
Crossref
Hans-Peter Voss, Rob Leurs, David Donnell & Aalt Bast. (1994) A new radioligand binding assay for cytochrome P450IID1 (CYP2D1) in rat liver microsomes: A tool to predict sparteine/debrisoquine type polymorphism of drugs. Journal of Pharmacological and Toxicological Methods 31:3, pages 149-152.
Crossref
Crossref
M.S. O'Mahony & K.W. Woodhouse. (1994) Age, environmental factors and drug metabolism. Pharmacology & Therapeutics 61:1-2, pages 279-287.
Crossref
Crossref
Y. M. Irshaid, H. F. Al-Hadidi & N. M. Rawashdeh. (1993) Dextromethorphan O-demethylation polymorphism in Jordanians. European Journal of Clinical Pharmacology 45:3, pages 271-273.
Crossref
Crossref
Alice M. Clark & Charles D. Hufford. (2006) Use of microorganisms for the study of drug metabolism: An update. Medicinal Research Reviews 11:5, pages 473-501.
Crossref
Crossref
G. Alván. (2009) Clinical consequences of polymorphic drug oxidation. Fundamental & Clinical Pharmacology 5:3, pages 209-228.
Crossref
Crossref
Kenneth M. Williams. 1991.
57
135
.
Satya S. Murthy, H.Umesha Shetty, Wendel L. Nelson, peter R. Jackson & Martin S. Lennard. (1990) Enantioselective and diastereoselective aspects of the oxidative metabolism of metoprolol. Biochemical Pharmacology 40:7, pages 1637-1644.
Crossref
Crossref
J. McAinsh & John M. Cruickshank. (1990) Beta-blockers and central nervous system side effects. Pharmacology & Therapeutics 46:2, pages 163-197.
Crossref
Crossref
J. Elks & C. R. Ganellin. 1990. Dictionary of Drugs. Dictionary of Drugs
344
475
.
PR Jackson, GT Tucker & HF Woods. (2012) Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism‐histograms and probit plots.. British Journal of Clinical Pharmacology 28:6, pages 647-653.
Crossref
Crossref
H. Umesha Shetty, Satya S. Murthy & Wendel L. Nelson. (2006) Stereospecific synthesis of specifically deuterated metoprolol enantiomers from chiral starting materials. Journal of Labelled Compounds and Radiopharmaceuticals 27:10, pages 1215-1226.
Crossref
Crossref
Kenneth M. Williams. (2007) CHIRALITY: PHARMACOKINETICS AND PHARMACODYNAMICS IN 3 DIMENSIONS. Clinical and Experimental Pharmacology and Physiology 16:6, pages 465-470.
Crossref
Crossref
N.R. Srinivas, J.W. Hubbard, E.M. Hawes, G. McKay & K.K. Midha. (1989) Enantioselective gas chromatographic assays with electron-capture detection for methoxyphenamine and its three primary metabolites in human urine. Journal of Chromatography B: Biomedical Sciences and Applications 487, pages 61-72.
Crossref
Crossref
M.S. Lennard. (1989) The polymorphic oxidation of beta-adrenoceptor antagonists. Pharmacology & Therapeutics 41:3, pages 461-477.
Crossref
Crossref
W. Kalow. 1989. Clinical Pharmacology in Psychiatry. Clinical Pharmacology in Psychiatry
148
162
.
M Eichelbaum, L Bertilsson, A Kupfer, E Steiner & CO Meese. (2012) Enantioselectivity of 4‐hydroxylation in extensive and poor metabolizers of debrisoquine.. British Journal of Clinical Pharmacology 25:4, pages 505-508.
Crossref
Crossref
M. Eichelbaum. (1988) Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochemical Pharmacology 37:1, pages 93-96.
Crossref
Crossref
David R. Webb, Vijendra KR. Singh, H. Hugh Fudenberg, Roger W. Russell, L. Öhman, G. Maluszynska, K.-E. MAgnusson, O. Stendahl, Peter A. Lambert, David H. P. Streeten, Gunnar H. AndersonJrJr, Vickram Ramkumar, George Pierson, Gary L. Stiles, Bernard Testa, Joachm M. Mayer, Duncan Stewart-Tull, Michael Williams, Gary L. Niel, Peter Hambleton, Stephen D. Prior, Andrew Robinson, Jed F. Fisher & Paul A. AristoffBernard Testa & Joachim M. Mayer. 1988. Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques
249
303
.
J. H. M. Schellens & D. D. Breimer. (1987) Variability in drug metabolism: importance of genetic constitution. Pharmaceutisch Weekblad Scientific Edition 9:2, pages 85-90.
Crossref
Crossref
L. J. Schaaf, S. C. Campbell, M. B. Mayersohn, T. Vagedes & D. G. Perrier. (1987) Influence of smoking and gender on the disposition kinetics of metoprolol. European Journal of Clinical Pharmacology 33:4, pages 355-361.
Crossref
Crossref
W. Kalow. (1987) Genetic variation in the human hepatic cytochrome P-450 system. European Journal of Clinical Pharmacology 31:6, pages 633-641.
Crossref
Crossref
W. Kalow. 1987. Human Genetics. Human Genetics
507
516
.